C. Ressayre-Djaffer

A randomised comparison of deferasirox<i>versus</i>deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Elliott Vichinsky, Onyinye Onyekwere, John B. Porter et al. · British Journal of Haematology · 2006 · 270 citations · Full text

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia

Maria Domenica Cappellini, Mohamed Béjaoui, Leyla Ağaoğlu et al. · Clinical Therapeutics · 2007 · 118 citations

Anemia, Patient-reported Outcomes, Iron Metabolism +4

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade®, ICL670) Is Well Tolerated and Reduces Iron Burden.

Elliott Vichinsky, R Fischer, Ellen B. Fung et al. · Blood · 2005 · 21 citations

P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload

Norbert Gattermann, M. Cazzola, Peter L. Greenberg et al. · Leukemia Research · 2005 · 16 citations

Hematological Malignancy, Oncology, Myelodysplastic Syndrome +8

Patient Satisfaction with Deferasirox (Exjade®, ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

Maria Domenica Cappellini, Mohamed Béjaoui, Leyla Ağaoğlu et al. · Blood · 2005 · 15 citations